| Title: |
LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN |
| Authors: |
Goldman, J.W.; Garassino, M.C.; Chen, Y.; Reinmuth, N.; Hotta, K.; Poltoratskiy, A.; Trukhin, D.; Hochmair, M.J.; Özgüroğlu, M.; Ji, J.H.; Statsenko, G.; Voitko, O.; Conev, N.V.; Bondarenko, I.; Spencer, S.; Xie, M.; Jones, S.; Franks, A.; Shrestha, Y.; Paz-Ares, L. |
| Contributors: |
AstraZeneca |
| Source: |
Annals of Oncology ; volume 31, page S1212-S1213 ; ISSN 0923-7534 |
| Publisher Information: |
Elsevier BV |
| Publication Year: |
2020 |
| Collection: |
ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1016/j.annonc.2020.08.2328 |
| Availability: |
https://doi.org/10.1016/j.annonc.2020.08.2328; https://api.elsevier.com/content/article/PII:S0923753420424196?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S0923753420424196?httpAccept=text/plain |
| Rights: |
https://www.elsevier.com/tdm/userlicense/1.0/ ; http://www.elsevier.com/open-access/userlicense/1.0/ |
| Accession Number: |
edsbas.A823D1ED |
| Database: |
BASE |